Skip Intro

Melinta Therapeutics

In November 2017, Deerfield committed up to $240 million to Melinta Therapeutics to fund the acquisition of the infectious disease business from The Medicines Company. Melinta is a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections. The products acquired include Vabomere, Orbactiv and Minocin IV.